GILDCL Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$79,000.00 |
| 52 Week High | US$79,000.00 |
| 52 Week Low | US$72,660.00 |
| Beta | 0.20 |
| 11 Month Change | 8.73% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 8.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| GILDCL | CL Biotechs | CL Market | |
|---|---|---|---|
| 7D | 8.7% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how GILDCL performed against the CL Biotechs industry.
Return vs Market: Insufficient data to determine how GILDCL performed against the CL Market.
Price Volatility
| GILDCL volatility | |
|---|---|
| GILDCL Average Weekly Movement | 2.6% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in CL Market | 0% |
| 10% least volatile stocks in CL Market | 0% |
Stable Share Price: GILDCL has not had significant price volatility in the past 3 months compared to the CL market.
Volatility Over Time: Insufficient data to determine GILDCL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| GILDCL fundamental statistics | |
|---|---|
| Market cap | CL$102.81t |
| Earnings (TTM) | CL$1.00t |
| Revenue (TTM) | CL$26.48t |
102.4x
P/E Ratio3.9x
P/S RatioIs GILDCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GILDCL income statement (TTM) | |
|---|---|
| Revenue | US$27.81b |
| Cost of Revenue | US$6.27b |
| Gross Profit | US$21.53b |
| Other Expenses | US$20.48b |
| Earnings | US$1.05b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | 0.85 |
| Gross Margin | 77.44% |
| Net Profit Margin | 3.79% |
| Debt/Equity Ratio | 128.3% |
How did GILDCL perform over the long term?
See historical performance and comparison